A Randomized, Double-Blind, Single-Dose, 5-Period Crossover Study to Evaluate the Efficacy, Safety, and Tolerability of E2086 Compared to Placebo and Active Comparator in Adult Subjects With Narcolepsy Type 1
Latest Information Update: 04 Mar 2025
At a glance
- Drugs E-2086 (Primary)
- Indications Narcolepsy
- Focus Therapeutic Use
- Sponsors Eisai Inc
- 25 Feb 2025 Planned End Date changed from 14 Feb 2025 to 17 Mar 2025.
- 25 Feb 2025 Planned primary completion date changed from 14 Feb 2025 to 17 Mar 2025.
- 25 Feb 2025 Status changed from recruiting to active, no longer recruiting.